IL4 and Alzheimer disease: These results indicate that DSMs contribute to the inhibition of AD lesion progression in vivo by decreasing IgE levels and modulating serum IL-4 levels in Dfb- or DNCB-induced AD mice, irrespective of Th1 polarization mediated by IFN-γ.